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ABSTRACT Immunization with sporozoites under chloroquine chemoprophylaxis
(CPS) induces distinctly preerythrocytic and long-lasting sterile protection against
homologous controlled human malaria infection (CHMI). To identify possible hu-
moral immune correlates of protection, plasma samples were collected from 38 CPS-
immunized Dutch volunteers for analysis using a whole Plasmodium falciparum pro-
teome microarray with 7,455 full-length or segmented protein features displaying
about 91% of the total P. falciparum proteome. We identiﬁed 548 reactive antigens
representing 483 unique proteins. Using the breadth of antibody responses for each
subject in a mixture-model algorithm, we observed a trimodal pattern, with distinct
groups of 16 low responders, 19 medium responders, and 3 high responders. Fifteen
out of 16 low responders, 12 of the 19 medium responders, and 3 out of 3 high re-
sponders were fully protected from a challenge infection. In the medium-responder
group, we identiﬁed six novel antigens associated with protection (area under the
curve [AUC] value of 0.75; P 0.05) and six other antigens that were speciﬁcally
increased in nonprotected volunteers (AUC value of 0.25; P 0.05). When used in
combination, the multiantigen classiﬁer predicts CPS-induced protective efﬁcacy with
83% sensitivity and 88% speciﬁcity. The antibody response patterns characterized in
this study represent surrogate markers that may provide rational guidance for clini-
cal vaccine development.
IMPORTANCE Infection by Plasmodium parasites has been a major cause of mortal-
ity and morbidity in humans for thousands of years. Despite the considerable reduc-
tion of deaths, according to the WHO, over 5 billion people are still at risk, with
about 216 million worldwide cases occurring in 2016. More compelling, 15 countries
in sub-Saharan Africa bore 80% of the worldwide malaria burden. Complete erad-
ication has been challenging, and the development of an affordable and effec-
tive vaccine will go a long way in achieving elimination. However, identifying
vaccine candidate targets has been difﬁcult. In the present study, we use a
highly effective immunization protocol that confers long-lasting sterile immunity
in combination with a whole P. falciparum proteome microarray to identify anti-
body responses associated with protection. This study characterizes a novel anti-
body proﬁle associated with sterile protective immunity and trimodal humoral
responses that sheds light on the possible mechanism of CPS-induced immunity
against P. falciparum parasites.
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Developing a vaccine against malaria remains a formidable challenge, with over 4decades of malaria vaccine clinical trials yielding only a single subunit vaccine,
RTS,S/AS01 (Mosquirix), that has been approved (1). Although the RTS,S vaccine averts
a substantial number of clinically symptomatic malaria infections in about 50% of
children, this protection wanes several months after vaccination (2, 3). Difﬁculties with
designing an effective vaccine for Plasmodium falciparum are compounded by a
complex multistage life cycle, extreme genetic diversity, and highly evolved immune
evasion mechanisms (4). The complexity of P. falciparum biology is further increased by
its large 23-Mb genome encoding more than 5,300 different proteins (5, 6). Predicting
which and how many of these proteins may induce protective immunity still remains
an elusive challenge exacerbated by difﬁculties in culturing sporozoites and preeryth-
rocytic stages of the parasite. Of the thousands of proteins expressed at any given time
during the P. falciparum life cycle, only a few have been tested as vaccine candidates
(7). Although both humoral and cellular responses have been associated with protec-
tion against malaria, there still remains the important question of which speciﬁc targets
confer protection (8–11). Development of a vaccine beneﬁts not only from immune
correlates that predict protection but also from a clearer understanding of the immune
mechanism of protection.
Advances in genomics, immunomics, and proteomics have beneﬁted studies aimed
at identifying immune correlates of protection and, more importantly, understanding
the molecular immune mechanisms of protection (4, 5, 12). The use of controlled
human malaria infection (CHMI) has enabled the development of very effective immu-
nization protocols, such as immunization with whole viable sporozoites under chloro-
quine chemoprophylaxis (CPS), radiation-attenuated P. falciparum sporozoites (RAS), or
genetically attenuated sporozoites (GAP) (13–15). Sterile homologous protection has
been a hallmark of CPS immunization since the ﬁrst immunization trial in 2009, in
which 100% of the volunteers immunized with 45 mosquito bites acquired long-
lasting immunity against malaria challenge infection (13, 16). In subsequent studies,
we showed that this protection is dose dependent and predominantly preerythro-
cytic (17, 18).
Understanding the contribution of humoral immune responses in this immunization
strategy is an important step toward elucidating the mechanism of protection and
designing next-generation vaccine strategies. This has been made possible by the
development of high-density whole-proteome microarrays that allow rapid interroga-
tion of humoral responses against infectious diseases for vaccine antigen discovery and
serodiagnostic antigen discovery (19–22). With over 5,300 protein-coding genes (5),
possible interactions of P. falciparum with the human immune system are complex, and
it is challenging to identify parasite antigens that induce protective immune responses.
In a previous study, we probed a partial P. falciparum proteome microarray containing
1,000 protein features and reported that CPS immunization induces a distinct antibody
(Ab) proﬁle compared to one induced by naturally acquired infection (22). For the
present study, we produced a more complete proteome array containing 7,455 features
representing 4,805 P. falciparum genes covering 91% of the P. falciparum proteome.
Here, we tested specimens from 3 consecutive CPS immunization trials with subse-
quent homologous challenge, involving a total of 30 fully protected and 8 nonpro-
tected individuals. Differences in Ab proﬁles between protected and nonprotected
volunteers identiﬁed antigens associated with CPS-mediated protective immunity and
others associated with susceptibility to infection. The antigens associated with protec-
tive immunity can be considered potential candidates for a multiantigen preerythro-
cytic vaccine to induce sterile protective immunity.
RESULTS
CPS immunization induces broad and variable humoral responses. Plasma
specimens from 38 volunteers enrolled in 3 clinical CPS immunization trials were
collected at 3 time points: (i) preimmunization (7 days before CPS immunization [I1-7]),
(ii) postimmunization (1 day before CHMI challenge [C-1]), and (iii) postchallenge
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(35 days postchallenge [C35]) (Fig. 1A). The heat map in Fig. 1B shows 548 immuno-
genic P. falciparum antigens that met the following two criteria: (i) seropositivity in
more than 15% of all the CPS-immunized volunteers (n 38) and (ii) antibody levels
doubled at C-1 compared to I1-7. Signal intensities measured at I1-7 were subtracted
from signal intensities at C-1 to control for background reactivity, and these data were
then used to create the heat map. The antibody reactivity proﬁles of the 38 CPS-
immunized individuals revealed great variability, with some volunteers showing intense
reactivity (high antibody levels) against a large number of antigens and others reacting
against a small number of antigens (Fig. 1B). Fourteen antigens were recognized by at
FIG 1 CPS immunization induces broad and variable humoral responses against P. falciparum antigens. (A) Plasma samples from 38 CPS-immunized volunteers
from 3 clinical trials (n 9 from study 1, n 5 from study 2, and n  24 from study 3) were probed on whole P. falciparum proteome microarrays. Thirty
CPS-immunized volunteers were protected and eight were not protected from malaria challenge. RBC, red blood cells. (B) Plasma samples collected
preimmunization (I1-7) and postimmunization/prechallenge (C-1) were probed, and signals were quantiﬁed. The heat map represents the signal intensity at
time point C-1, corrected for background reactivity by subtracting the signal intensity at I1-7, against 548 immunogenic P. falciparum features (or 483 unique
proteins) printed on proteome microarrays. For an antigen to be considered immunogenic, (i) its levels had to have increased 100% at C-1 compared to I1-7
and (ii) its seroprevalence had to be 15%. The specimens are ordered in clinical groups, nonprotected (n 8) and protected (n 30). Samples are arranged
with increasing reactivity from left to right, while the antigens are arranged with decreasing reactivity from top to bottom. A color gradient is used to display
the signal intensity detected for each antigen, as shown by the key. (C) Comparison of aggregated C-1 reactivity of the 548 immunogenic antigens among the
3 different immunization dose groups. During the 3 rounds of immunization, 10, 9, and 19 volunteers received 5, 10, and 15 mosquito bites, respectively. Dots
show individual data points, center lines show the medians, box limits indicate the 25th and 75th percentiles, and whiskers extend 1.5 times the interquartile
range (IQR). Aggregate antibody levels were compared using the Kruskal-Wallis rank sum test. To detect only malaria-speciﬁc responses, the I1-7 responses were
subtracted from the C-1 responses.
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least 50% of the volunteers, with the top ﬁve most commonly recognized antigens
being CSP (89% of volunteers), LSA1 (82%), LISP2 (71%), EXP1 (66%), and MSP2 (63%)
(see Table S1 in the supplemental material).
For this analysis, specimens from 3 studies were combined to create 3 dose groups.
The ﬁrst group of 10 volunteers received a total of 15 infectious mosquito bites, the
second group of 9 volunteers received 30 mosquito bites, and the third group of 19
volunteers received 45 mosquito bites over a period of 3 months (Fig. 1A). To study the
effect of immunization dose on antibody response, we summed up each individual’s
response against the 548 immunogenic antigens (Fig. 1C). There was no signiﬁcant
difference in the aggregate P. falciparum antigen-speciﬁc IgG levels between the 3
mosquito bite dose groups (P 0.56 by the Kruskal-Wallis test). Since the dose of
immunization does not account for the observed antibody reactivity differences in the
subsequent analyses, we used two metrics, “breadth” and “magnitude,” to further
assess the association between the antibody responses and protection.
CPS immunization induces trimodal IgG responses. In the present study, a
two-component mixture model was used to determine the breadth count for each
individual specimen (see Materials and Methods and Fig. S1). There was considerable
interindividual variation in the breadths of the induced antibody speciﬁcities, with
some individuals reacting to as few as 9 antigens, while the strongest responder
reacted to 881 antigens. Some of the subjects had low responses to a small number of
antigens, while others had high responses to many antigens. We constructed and
applied a three-component mixture model on the breadth counts of all the subjects,
which clustered the different distributions of antibody breadth proﬁles into three
distinct groups (Fig. 2A). Using this model, two cutoff points (180 and 681 antigens)
were identiﬁed, which separated the three groups of responders. One group responded
to a limited number of antigens (breadth range, 9 to 177) (low responders). The second
group reacted to a moderate number of antigens (breadth range, 199 to 549) (medium
responders), while the third group was highly reactive against a large number of
antigens (breadth range, 794 to 881) (high responders) (Fig. 2B). Fifteen of the 16 low
responders, 12 of the 19 medium responders, and all the high responders were
protected from malaria challenge (Fig. 2B). Antibody reactivity at C35 in protected
individuals, irrespective of their responder status, was stable or declined compared to
C-1 levels, except for reactivity against CSP, which increased in all groups (Fig. 2C). In
contrast, nonprotected individuals showed a markedly increased response upon chal-
lenge, consistent with data from other studies (20, 23); the appearance of new antigens
from a productive infection leads to a robust antibody response against blood-stage
antigens, whereas sterile protection prevents the presentation of new blood-stage
antigens to the immune system, and responses do not change after challenge. Low
responder referred to all subjects who recognized fewer than 180 proteins. However, it
is important to note that low responders also had lower average signal intensities seen
at C-1 and C35 (Fig. 2C) against the top 50 most reactive antigens after challenge
(Table S2).
Stage of expression of proteins recognized by CPS-immunized subjects. In
order to characterize the distribution of the proteins recognized by CPS-immunized
subjects at different stages of the P. falciparum life cycle, we downloaded protein
annotations from PlasmoDB with tandem mass spectrometry (MS/MS) evidence for
expression (see Materials and Methods). Of the 5,305 protein-coding genes annotated
in PlasmoDB (6), MS/MS evidence of expression is available for 4,216 proteins. We
aligned the Ab reactivities with this MS evidence of expression and tabulated (Table S1)
and plotted (Fig. 3) the results. Of the 4,768 unique proteins printed on the microarray,
252 and 1,427 are exclusively expressed by sporozoites and blood-stage parasites,
respectively. A total of 2,100 antigens are commonly expressed at both stages, while
989 proteins recognized by CPS-immunized subjects lack MS evidence of expression
(Fig. 3A).
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Overall, nonprotected subjects recognized more antigens than protected subjects at
all stages tested (Fig. 3B and Table S1). Nonprotected subjects recognized 9% (23) and
11% (160) of the proteins expressed uniquely at sporozoite and blood stages, respec-
tively. They also recognized 12% (252) of the proteins expressed at both stages (Fig. 3B).
On the other hand, protected subjects recognized 1% (3) of the proteins uniquely
expressed by sporozoites, 4% (58) of the proteins exclusively expressed at blood stages,
and 6.5% (136) of the proteins expressed at both stages and printed on the array
(Fig. 3B). As expected, medium and high responders reacted to more antigens than did
low responders. Most of the antigens recognized by medium and high responders are
commonly expressed at sporozoite and blood stages (Fig. 3C). Interestingly, CSP is the
only sporozoite protein recognized by low responders. Furthermore, they respond to
0.6% (9) of the proteins expressed at the blood stage and 0.8% (16) of the proteins
expressed at both stages (Fig. 3C). Medium and high responders recognized 8% (17),
16% (326), and 12% (165) of the proteins expressed at the sporozoite stage, the blood
FIG 2 CPS immunization induces trimodal IgG responses in previously malaria-naive adults. (A) Three-component mixture model for breadth counts observed
in CPS-immunized individuals (n 38). The solid curved lines show the ﬁtted breadth count distributions in the mixture model. The dashed curve line shows
the mixture-model ﬁt for components 1 (orange), 2 (blue), and 3 (green). The two dashed straight lines show the estimated cutoff points at 180 and 681
antigens, which distinguish the different responder groups (low, medium, and high responders). The histogram represents the frequency of the breadth counts
in the different bins. Breadth counts are ranked from the lowest to the highest (range, 9 to 881). (B) Box plots of low-, medium-, and high-responder groups
showing protected and nonprotected volunteers. Comparison of breadth counts within the medium-responder group was performed by a Wilcoxon rank sum
test. Gray dotted lines show the cutoff points between responder groups. Dots show individual data points, center lines show the medians, box limits indicate
the 25th and 75th percentiles, and whiskers extend to show the minimum and maximum breadth counts. (C) Humoral reactivity was compared prechallenge
(C-1) and post-CHMI challenge (C35). Mean antibody signal intensities measured against the top 50 most reactive antigens after CHMI challenge are shown,
comparing low, medium, and high responders. The medium-responder group is further stratiﬁed into protected (“Med-P”) and nonprotected (“Med-NP”)
volunteers. The mean reactivities of the top 5 most seroprevalent antigens, CSP, LSA1, LISP2, EXP1, and MSP2, are shown. Black dotted lines indicate the other
boosted antigens after challenge (see Table S2 in the supplemental material).
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stage, and both stages, respectively. The gene annotations and protein names are
shown in Table S1.
Novel antibodies associated with CPS-induced sterile protection. Our data show
trimodal humoral responses with low, medium, and high responders. We hypothesized
that protected low responders were protected from CHMI by cellular responses against
sporozoite and early-liver-stage antigens, preventing exposure to late-liver-stage and
blood-stage antigens. This low parasite load therefore results in the low breadth count.
On the contrary, medium/high responders do not clear early-liver-stage parasites, the
parasites progress through later stages, and the subjects acquire higher breadth counts.
Based on this hypothesis and the fact that there was only one nonprotected subject in
the low- and high-responder groups, we analyzed antibody responses associated with
protection in the medium-responder group only.
Antibody targets associated with sterile protective immunity were identiﬁed by
comparing 7 nonprotected and 12 protected medium responders (Fig. 2B). All 548
immunogenic antigens were individually tested in univariate analysis by (i) performing
a Wilcoxon rank sum test (Fig. 4A) (with multiple-testing correction) and (ii) construct-
ing receiver operating characteristic (ROC) curves and calculating the area under the
FIG 3 Stage of expression of proteins printed on the microarray. Publicly available tandem mass spectrometry (MS/MS) data on protein expression were
obtained from PlasmoDB. (A) Venn diagram showing stage-speciﬁc proﬁles of the proportions of proteins expressed by sporozoite and blood stages with MS/MS
evidence of expression and printed on the microarray. (B and C) Bar plots showing numbers of P. falciparum proteins uniquely or commonly expressed at
sporozoite and/or blood stages and recognized by at least 25% of nonprotected or protected volunteers (B) or low, medium, and high responders (C). The
names and gene annotations of these proteins are indicated in Table S1 in the supplemental material.
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FIG 4 Novel antigens associated with CPS immunization-induced sterile protection. (A) Differential signal intensities of 229 antigens at C-1 in plasma samples
of protected (n 7) and nonprotected (n 12) medium responders. The red dotted line indicates the threshold P value of 0.05; dots in the green area and
dots in the orange area represent antigens signiﬁcantly more reactive in protected and nonprotected subjects, respectively. (B) Gene identiﬁcations of the
antigens associated with protection and susceptibility in medium responders. Wilcoxon rank sum test P values (Wilcox Pval), Wilcoxon rank sum test P values
with Benjamini-Hochberg correction for multiple comparisons (Wilcox Pval BH), area under the receiver operating characteristic curve (AUC) values, and
leave-one-out cross-validation (LOOCV) AUC values for protected and nonprotected volunteers are shown. (C and D) Speciﬁc antigens associated with
protection (C) or susceptibility (D). Boxes represent individual antigens in nonprotected (orange) (n 7) and protected (green) (n 12) subjects. Dots show
individual data points, center lines show the medians, box limits indicate the 25th and 75th percentiles, and whiskers extend 1.5 times the IQR. Comparisons
were tested by a Wilcoxon rank sum test.
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ROC curve (AUC) values for each antigen (Fig. 4A). Using an AUC value cutoff of 0.75
and a Wilcoxon P value of 0.05, we identiﬁed antibody responses against six novel P.
falciparum-speciﬁc targets associated with sterile protection (Fig. 4A and B); we also
identiﬁed six antigens that had signiﬁcantly increased antibody responses in nonpro-
tected individuals, with an AUC value of0.25 and a Wilcoxon P value of0.05 (Fig. 4A
and B). CPS-immunized subjects are exposed to parasitemia during the ﬁrst immuni-
zation, and in some subjects, there is recurrent exposure to parasitemia in subsequent
immunizations. Even though both protected and nonprotected subjects undergo
similar infections during immunization, protected individuals do not recognize four of
the antigens associated with susceptibility, which is indicative of protection status. In
comparison, nonprotected subjects show higher-magnitude reactivity to all six antigen
“susceptibility markers” (Fig. 4D). In order to check for generalizability of the data from
ROC analysis, we also performed leave-one-out cross-validation (LOOCV) analysis on the
two sets of antigens (Fig. 4B). The magnitude of signal intensities for each of the six
antigens associated with protection was signiﬁcantly higher in protected than in
nonprotected volunteers (Fig. 4C). Inversely, the six antigens associated with suscep-
tibility to malaria showed a higher magnitude in nonprotected than in protected
individuals (Fig. 4D). We also repeated the above-described univariate analysis on the
immunogenic antigens after excluding all antigens with MS evidence of expression at
blood stages. Of the 483 unique immunogenic proteins on the array, 149 of these were
exclusively expressed at blood stages. Therefore, the analysis was performed on 334
proteins represented by 391 features on the array. Five of the six antigens
(PF3D7_0313200, PF3D7_1007700, PF3D7_1012700, PF3D7_1364400, and PF3D7_
0925800) associated with protection in our previous analysis were also identiﬁed by this
analysis (data not shown). Even though the well-studied antigens CSP, LSA1, LISP2,
EXP1, and MSP2 were highly seroprevalent and in some studies used as vaccine targets
(2, 3, 24–26), they were not associated with protection or susceptibility either individ-
ually or in combination (Fig. S2).
The breadth of antibodies classiﬁes protected and nonprotected volunteers.
We compared protective and susceptible seropositivity counts (Fig. 5A and B and
Table S3). As expected, protected medium responders had higher protective seropos-
itivity counts than nonprotected medium responders. The reverse was true for suscep-
tible seropositivity counts. We further compared the aggregate IgG responses associ-
ated with protection and susceptibility (Fig. 5C and D). The aggregate IgG responses
associated with protection (Fig. 5C) and those associated with susceptibility (Fig. 5D)
were higher in protected and nonprotected medium responders, respectively. High
responders (all protected) had the highest protective seropositivity counts and similarly
the highest aggregate IgG responses. Although high responders had susceptible
seropositivity counts similar to those of nonprotected medium responders, the aggre-
gate IgG levels were much lower. Low responders had low responses on both metrics.
To test whether the difference between protective seropositivity counts and suscepti-
ble seropositivity counts could discriminate protected from nonprotected CPS-
immunized subjects, we performed both ROC curve and LOOCV analyses. We con-
structed an ROC curve after subtracting susceptible seropositivity counts from
protective seropositivity counts for each subject, which predicted protected subjects
with 83% sensitivity and 88% speciﬁcity (AUC value of 0.89) and an LOOCV AUC value
of 0.86 (Fig. 5E). The combined results suggest that these two distinct classes of
antigens can be used together in a serodiagnostic test to predict outcomes after CPS
immunization.
DISCUSSION
Using a comprehensive P. falciparum protein microarray covering approximately
91% of the P. falciparum proteome, we show that the antibody speciﬁcities of CPS-
immunized volunteers react to a broad repertoire of antigens, with substantial inter-
individual variability in both breadth and magnitude. We identiﬁed 548 antigens
(fragments) reactive in more than 15% of the CPS-immunized individuals, which
Obiero et al.
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FIG 5 Breadth of antigen response as a correlate of protection. (A and B) Breadth counts of protective (A) and nonprotective (B) antigens in protected (n 30)
and nonprotected volunteers (n 8). Dots show individual data points, center lines show the medians, box limits indicate the 25th and 75th percentiles, and
whiskers extend 1.5 times the IQR. Antibody intensities were compared using the Wilcoxon rank sum test. (C) The difference between protective and susceptible
seropositivity counts was used to construct an ROC curve. LOOCV analysis was also performed. An AUC value of 0.5 indicates that there is no difference between
the groups.
Novel Antibody Targets Associated with Malaria Immunity
January/February 2019 Volume 4 Issue 1 e00027-19 msphere.asm.org 9
 o
n
 April 1, 2019 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
represent 483 unique P. falciparum proteins. The breadths of the antibody responses
among protected individuals varied from recognition of as few as nine to several
hundred antigens. The breadths of the responses showed a trimodal distribution, and
immunized individuals could be classiﬁed into high, medium, and low responders. Our
data show that protection is not directly associated with breadth of response, as 15 out
of 16 low responders were protected. From the medium-responder group, six antigens
stand out, which were signiﬁcantly more reactive in protected individuals, while levels
of another 6 “susceptibility antigens” were elevated in nonprotected individuals.
To better quantify antibody breadth and deﬁne the positivity of a signal, we
developed a new computational approach that takes the variable baseline reactivity
between individuals into consideration. The approach uses a mixture model where all
antigens’ signal intensities were used to model two distributions (low and high). The
mean and standard deviation (SD) of the lower distribution were used to set the
threshold for classifying seropositive antibodies for that sample. In our previous studies,
seropositive responses were deﬁned by creating a cutoff point using the mean reac-
tivity against in vitro transcription and translation (IVTT) controls from all volunteers in
the study (global threshold). This IVTT control signal intensity is proportional to the
amount of anti-Escherichia coli Ab in the sample, which varies depending on the
individual. Importantly, our approach uses antimalaria reactivity for deﬁning the thresh-
old rather than the anti-E. coli reactivity that was used previously (19–21). While care is
taken to block all reactivity against E. coli antigens, depending on the subjects’ disease
history, this varies between subjects. Therefore, the use of anti-P. falciparum responses
rather than reactivity against E. coli as the basis for specifying seropositivity makes the
analysis more speciﬁc for P. falciparum. The new method treats each volunteer indi-
vidually, thereby limiting “missed reactive antigens” in low-responding volunteers,
which would occur when a global median cutoff is used.
Here, we show that CPS immunization is associated with an interesting dichotomy
between the breadth of seropositive antigens and sterile protection; 42% of the
volunteers develop low breadth counts, while 58% have intermediate to high breadth
counts. While this unpredicted pattern does not correlate with protection, it shows how
variable humoral responses against P. falciparum can be. While our study provides
insights into immune-mediated protection from malaria, it also shows that antibody
responses are associated with protection in about 50% of the subjects. Immune
response variability in CHMI has also been shown by Burel et al., who reported high
expression levels of a set of microRNAs that correlated with high cellular and antibody
responses seen in CHMI volunteers (27). These studies highlight the need for a better
understanding of immune responses against malaria. It remains to be seen whether the
observed variable patterns in CPS-immunized subjects are driven by genetics, age, or
other factors.
Interestingly, 15 of the 16 volunteers classiﬁed as low responders were protected
from CHMI in spite of the low breadth counts. In contrast, 7 out of the 8 nonprotected
individuals had higher breadth counts than the protected low responders. It is note-
worthy that the 1 nonprotected individual who was classiﬁed as a low responder
actually had the highest breadth count of that group (177), close to the breadth count
cutoff of 180, which would put this individual into the medium-responder category.
There was no signiﬁcant difference in the breadth counts between protected and
nonprotected medium responders; however, their overall responses to challenge were
distinctly different. A likely explanation is that cellular immune responses against
early-liver-stage development protect these volunteers in the humoral low-responder
group, resulting in reduced exposure to later-stage P. falciparum antigens and, hence,
limited antibody reactivity to a small repertoire of antigens. Indeed, production of
gamma interferon (IFN-), tumor necrosis factor (TNF), and interleukin-2 (IL-2) by CD4
T cells has been associated with preerythrocytic protection following CPS immunization
and natural infection (13, 28, 29). However, it has also been reported that antibodies
from CPS-immunized and protected human volunteers inhibit sporozoite traversal
through hepatocytes and reduce liver-stage infection in the human liver chimeric
Obiero et al.
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mouse model. Protected medium and high responders may be protected by a broader
repertoire of antibodies against late-liver-stage parasite antigens. Indeed, low respond-
ers show signiﬁcantly lower antibody responses against the mid/late-liver-stage anti-
gens LSA1 and LISP2 than medium/high responders. There was no difference in
reactivities against the sporozoite/early-liver-stage antigen CSP and a blood-stage
antigen, EXP1. EXP1 is also expressed at the liver stage, and it contains 15-amino-acid
region of homology to the NANP repeat sequence on CSP, an immunodominant
epitope shown to be responsible for cross-reactivity (30, 31). Therefore, this may explain
the similar reactivities in low and medium/high responders against both CSP and EXP1.
MSP2, a blood-stage antigen, is not recognized in low responders but is well recognized
in the medium/high responders (32). Even though anti-CSP antibodies are not associ-
ated with protection in the present study, immune responses against CSP or other
intrinsic sporozoite antigens may limit infection of liver cells, leading to low-level
recognition of other liver-stage/blood-stage antigens and the low-responder pheno-
type.
Despite the fact that chloroquine works by preventing parasites from developing in
red blood cells (33), CPS-immunized subjects still recognize more blood-stage-
expressed proteins than those coexpressed at the sporozoite stage. This could be
explained by the fact that during immunization, there is exposure to the ﬁrst wave of
mature and fully developed blood-stage parasites emerging from infected liver cells
(13, 18, 34). In addition, compared to blood stages, sporozoites are seen for only a few
hours while in the bloodstream before reaching the liver, where they grow and divide.
The antigenic load favors the blood stages, as each infected liver cell releases tens of
thousands of merozoites into the bloodstream (35, 36). Due to the technical difﬁculties
involved in culturing preerythrocytic stages of P. falciparum, there should be more
protein expression studies conducted on blood stages of P. falciparum, which can be
cultured with relative ease.
Whether or not responses against these proteins exclusively expressed at blood
stages are important in CPS-induced protection is not known. The exclusion of proteins
exclusively expressed in blood stages does not drastically change the results of our
analysis. Only one of the proteins identiﬁed is expressed at blood stages according to
MS data (see Table S1 in the supplemental material). In order to capture antigens
associated with both protection and susceptibility, we performed univariate analysis on
all immunogenic proteins. It is important to note that the MS data available are not fully
comprehensive, and there are hundreds of proteins with no expression data. The
addition of more expression data will greatly beneﬁt the comparison of stages of
expression and immunogenicity.
Naturally acquired immunity (NAI) is associated with increased breadth and intensity
of the humoral response against dozens of blood-stage parasite antigens and increased
protection from clinical malaria, but NAI does not induce sterile immunity (22, 37). In
contrast, most of the sterilely protected CPS-immunized volunteers are able to control
liver-stage parasites after 2 rounds of immunization, and as a consequence, they do not
have measurable blood-stage parasites after the third immunization (18, 34). In the
present study, we show that in volunteers with sterile protection from challenge, there
is no boosting of speciﬁc antibodies except for CSP, which indicates exposure of these
volunteers only to sporozoites but not to blood-stage parasites during challenge. This
ﬁnding is consistent with the induced preerythrocytic immunity that prevents para-
sitemia (18, 34). Conversely, nonprotected volunteers have increased reactivity against
hundreds of antigens after challenge, which indicates exposure to both sporozoites and
blood stages. These results corroborate data from our previous studies showing that
protected subjects boost antibody responses only to CSP and that nonprotected
volunteers undergo recurrent parasitemia during immunizations (17, 34). This also
explains why nonprotected volunteers have signiﬁcantly higher antibody responses
against antigens associated with susceptibility, 5 out of 6 of which are well-
characterized blood-stage antigens. The number of mosquito bites during CPS immu-
nization is an important denominator for blood-stage exposure during immunization in
Novel Antibody Targets Associated with Malaria Immunity
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both protected and nonprotected volunteers (17, 34). Protection, at least for the
medium-responder group, seems to be associated with antibody responses against a
panel of six antigens. Even though low responders had a minimal-magnitude response
to a few antigens, 94% of them were protected from malaria challenge. Interestingly,
low responders boost reactivity against CSP only after challenge, suggesting that the
immune system is able to respond to and clear the sporozoites quickly after infection.
Previously, Bijker et al. showed that protection after CPS immunization was associated
with higher proportions of CD4 and CD8 cytotoxicity markers (17). We did not see an
association of protection in low responders with responses against the set of antigens
identiﬁed in the medium-responder group. High responders were highly reactive
against hundreds of antigens, and the synergistic effect of responses against these
antigens could play a role in the protection seen.
Of note, several studies have associated both the breadth and magnitude of
antibody responses with protection against malaria (37, 38). In the present study,
responses against MAEBL, TRAP, and SEA1 were not associated with protection after
CPS immunization, in contrast to a previous study conducted on samples from CPS-
immunized individuals (38). The most intensely reactive antigens following CPS immu-
nization, CSP, LSA1, LISP2, EXP1, and MSP2, are well-established vaccine candidates.
Previously, our group has shown that CSP, LSA1, and MSP2 are highly reactive after CPS
immunization (22). Furthermore, both LSA1 and LISP2 have been shown to be highly
reactive in a PfSPZ-CVac vaccine trial (39). Our study shows that antibodies against
these highly immunogenic antigens were not associated with CPS-mediated protection
in combination or individually. This indicates that, at least in the case of CPS immuni-
zation, antibody responses against these immunodominant antigens do not necessarily
equate with protection, but they may be markers of exposure. This is interesting in light
of diverse results in both human and animal trials with CSP, the major vaccine
candidate in clinical development (2, 3, 40, 41).
Importantly, protection in this study is associated with responses against six novel
antigens, three of which are conserved proteins with unknown function, an armadillo
repeat protein (PF3D7_0925800), NLI-interacting factor-like phosphatase (PF3D7_
1012700), and a transcription factor (PF3D7_1007700). Of the conserved proteins,
PF3D7_0313200 is predicted to be a DNA binding protein. The are no MS/MS data
available for this protein, although the transcript has been detected in both sporozoites
and gametocytes by transcriptome sequencing (RNA-Seq) studies. It is thought to be
located on the cell surface, cytoplasm, or apicoplast (42). PF3D7_1136200 has a signal
peptide and is predicted to be an anchored component of the plasma membrane.
There is evidence from RNA-Seq studies showing that it is expressed by sporozoites,
late trophozoites, and gametocytes. However, MS/MS studies show that the protein is
present only in merozoites and schizonts (6, 42–45). PF3D7_1364400 has two trans-
membrane domains and an extracellular region; MS/MS and proteome studies have
shown that it is expressed by both sporozoites and blood stages (6, 46, 47).
PF3D7_0925800 is predicted to be located in the cytoplasm and is involved in RNA
metabolic processes. Its expression has been shown in sporozoites, trophozoites, and
gametocytes (6, 46, 48, 49).
PF3D7_1012700, a member of the NIF family, is located in the nucleus and has been
shown to be important in drug responses (6, 50–52). This protein has been found in
sporozoite, schizont, trophozoite, and gametocyte life stages (43, 47, 53). The 26-
member AP2 gene family has been shown to have a variety of roles in gene expression
(54–56). Speciﬁcally, PF3D7_1007700, a member of the ApiAP2 family of DNA binding
proteins, is associated with the regulation of genes involved in invasion (56–58). Both
MS/MS and RNA-Seq data show that this protein is expressed in sporozoites and blood
stages of the parasite (6, 42, 49, 53, 59–61). Interestingly, another member of this family,
PF3D7_0420300, was preferentially more reactive in protected volunteers although
with borderline signiﬁcance (P 0.059). Moreover, the antibody response against
PF3D7_1139300, another ApiAP2 gene, was associated with protection in a study where
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individuals were immunized with irradiated sporozoites via bites from infected mos-
quitoes (23).
Our study has identiﬁed 6 antigens associated with susceptibility and 6 antigens
associated with protection. When used together, the combined set predicts protection
among all the CPS-immunized volunteers with 83% sensitivity and 88% speciﬁcity.
The 6 previously unrecognized antigens associated with sterile protection in this
study are potential vaccine antigen targets.
MATERIALS AND METHODS
Study population. Studies from our group have shown that immunization of healthy human
volunteers via bites of P. falciparum-infected mosquitos under chloroquine prophylaxis (CPS immuniza-
tion) induces sterile preerythrocytic protection against controlled human malaria infection (CHMI). In
these studies, sterile protection is deﬁned as the absence of infected red blood cells on thick blood
smears during the 21-day follow-up after challenge. In the ﬁrst study (ClinicalTrials.gov registration
number NCT00442377), 10 healthy malaria-naive Dutch volunteers received 15 infective mosquito bites
and were completely protected (13, 22); plasma samples from 9 of these volunteers were available for
this study. In the second study (ClinicalTrials.gov registration number NCT01236612), 5 of the CPS-
immunized volunteers were fully protected. However, for the purpose of this study, one immunized
individual later developed parasitemia on day 21 after sporozoite challenge (retrospectively detected by
quantitative PCR [qPCR]) and therefore was considered nonprotected (18). In the third study (Clinical-
Trials.gov registration number NCT01218893), healthy volunteers received CPS immunization with bites
from graded numbers of P. falciparum-infected mosquitoes (three rounds of infection by 15 mosquito
bites [3 15] [n 5], 3 10 [n 9], or 3 5 [n 10]); 4 out of 5 subjects in the 3 15 group, 8 out of
9 subjects in the 3 10 group, and 5 out of 10 subjects in the 3 5 group were protected against
challenge infection (16). Citrate plasma samples from all three studies were collected longitudinally at
three time points (7 days before CPS immunization [I1-7], 1 day before CHMI challenge [C-1], and 35 days
postchallenge [C35]), probed, and analyzed for this study. In total, we had 30 protected and 8
nonprotected individuals from these studies.
Microarray construction. We constructed whole Plasmodium falciparum 3D7 (Pf3D7) proteome
microarrays with 7,455 full-length or segmented protein features displaying about 91% of the P.
falciparum proteome (Antigen Discovery, Inc., Irvine, CA). Sequence-veriﬁed polypeptides were printed as
in vitro transcription and translation (IVTT) reactions as previously described (39). These 7,455 P. falci-
parum open reading frames (ORFs) represent 4,768 unique genes. T7 promoter plasmids encoding each
protein used in the IVTT reactions were obtained using a high-throughput cloning method described
previously (18). Quality control of array slides was performed as described previously (22), with a 97%
protein expression efﬁciency of the IVTT reactions spotted.
Protein microarray probing. P. falciparum-speciﬁc plasma antibodies induced by CPS immunization
bind to their cognate spotted IVTT antigen/polypeptide, which is detected and quantiﬁed using
ﬂuorescent secondary antibodies, akin to Western blotting. Plasma samples were diluted 1:200 in protein
array blocking buffer (Whatman, Inc., Sanford, ME) supplemented with a 10% (vol/vol) E. coli DH5 lysate
(MCLAB, San Francisco, CA) and incubated on arrays overnight at 4°C. Blocking of anti-E. coli antibodies
prevents binding of any anti-E. coli antibodies in plasma samples and thus reduces the background.
Slides were blocked in protein array blocking buffer (Whatman, Inc., Sanford, ME) for 30 min and then
incubated with plasma for 2 h at room temperature. Bound antibodies were detected by incubation with
biotin-SP-conjugated afﬁnity-puriﬁed goat anti-human IgG Fc fragment-speciﬁc secondary antibody
(Jackson ImmunoResearch, West Grove, PA) diluted 1:200 in protein array blocking buffer (Whatman, Inc.,
Sanford, ME), followed by streptavidin-conjugated SureLight P-3 (Columbia Biosciences, Columbia, MD).
The microarrays were scanned with a GenePix 4200 AL microarray scanner (Molecular Devices, Sunny-
vale, CA). Microarray spot intensities were quantiﬁed using the ProScanArray Express microarray analysis
system (PerkinElmer LAS, Waltham, MA) with spot-speciﬁc background correction. The raw values from
array scans were the mean intensities of all the pixels in printed spots after subtracting surrounding
background intensities for each protein or negative control. IVTT controls, or ‘‘no-DNA’’ controls, are
negative-control spots consisting of IVTT reaction mixtures without the addition of a plasmid template.
The IVTT control spots on each array were averaged, and this value was subtracted from the values for
every other spot on the array. Samples probed on different days and from different batches of slides were
correlated, showing that slide printing and probing were reproducible.
Data normalization, analysis, and statistics. All analyses were performed using the R statistical
environment and “ggplot2,” an R package used to visualize the data (62, 63). Univariate logistic
regression was used to examine the association of protection status and reactivity against malaria
antigens. To account for differences in baseline antibody responses seen among the different immunized
individuals and to detect only antibodies induced by CPS immunization, preimmunization (I1-7), baseline
antibody levels for each antigen were subtracted from the data generated using matched subsequent
prechallenge (C-1) and postchallenge (C35) plasma samples for each individual. The analysis reported
here uses a new metric for deﬁning reactive antigens. We used a computational approach using the R
package “mixtools” (64) to quantify each volunteer’s antibody responses at given time point. This
package allows for the clustering of observations (antibody responses) that are assumed to have arisen
from a mixture of ﬁnite distributions (positive and negative antibody responses).
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In previous studies from our group, we used the average of negative-control spots (IVTT control spots
[no-DNA negative controls]) from all volunteers to create a global median cutoff point; antibody
responses above this cutoff were classiﬁed as seropositive (positive antibody response), and those below
it were classiﬁed as seronegative (negative antibody response) (19–21). In present study, the mixture
model was constructed using each subject’s antibody responses at all the time points (seroreactivity)
against all antigens (7,455 antigens). The two-component mixture model identiﬁes the positive and
negative antibody distributions, thereby allowing us to set the cutoff point as the mean of the negative
antibody signal distribution plus 3 standard deviations (SD) (see Fig. S1 in the supplemental material). For
better visualization of the low-frequency high-signal-intensity data points, the horizontal axis scale was
square-root transformed using the function sqrt_trans() in the “scales” R package. Using this cutoff point,
we identiﬁed seropositive and seronegative antibody responses (responses above or below the individ-
uals’ cutoff, respectively). Importantly, this tool takes the intrinsic interindividual baseline variability in
each subject’s specimen into consideration, and therefore, the unbiased cutoff point varies between
individuals. Immunogenic antigens were deﬁned as antigens with a seropositive antibody response and
a 2-fold increase in the antibody response at C-1 compared to that at I1-7. For each subject, the total
numbers of antigen targets that were immunogenic (breadth) were calculated. For protein features to be
considered reactive at the population level, they had to be immunogenic in more than 15% of all the
immunized subjects (Table S1). Only antigens considered reactive based on these criteria were used for
subsequent analysis.
The reactive antigens were tested for differences in antibody levels and breadth counts comparing
CPS-immunized protected and nonprotected individuals using a two-tailed Wilcoxon rank sum test. A
Kruskal-Wallis rank sum test was used to test for differences in variables that had more than two groups.
Results were considered statistically signiﬁcant when P values were 0.05. P values were corrected for
multiple testing by adjusting the false discovery rate (FDR) using the Benjamini-Hochberg procedure as
applied by the p.adjust() R function (65). Furthermore, we tested each individual antibody’s performance
in predicting protection by constructing receiver operating characteristic (ROC) curves and calculating
the area under the curve (AUC). Protected individuals were labeled with positive class labels; therefore,
an AUC value of0.5 showed that the speciﬁc antibody levels were associated with protection and were
higher in protected than in nonprotected volunteers. An AUC value of 0.5 indicated that the speciﬁc
antibody levels were lower in protected volunteers and therefore associated with susceptibility to
malaria. To test for generalizability of our regression model, we also performed leave-one-out cross-
validation (LOOCV). LOOCV was done for each protective/susceptible antigen; one sample was omitted
from the data set (test set), and a regression model was built on the remaining data (training set). The
model is tested for generalizability by predicting the status of the omitted sample. This is repeated, each
time with a different sample left out, until all the samples have been omitted once.
In order to assess whether the protective seropositivity counts (numbers of seropositive responses to
antigens associated with protection) were more important for protection than susceptible seropositivity
counts, we determined the difference between protective seropositivity counts and susceptible sero-
positivity counts and then used this difference to construct an ROC curve. LOOCV analysis was also
performed for this model. Comprehensive descriptions of the cohorts compared are provided in the
corresponding ﬁgure legends.
Plasmodium falciparum protein expression. There are 5,305 P. falciparum 3D7 protein-coding
genes identiﬁed in PlasmoDB (6) (version 38; http://plasmodb.org/plasmo/). All gene annotations with
tandem mass spectrometry (MS/MS) evidence of expression were downloaded from PlasmoDB. MS/MS
studies have identiﬁed 248,678 peptides that map to 4,216 P. falciparum proteins. Due to the fact that
some of the P. falciparum stages are not easily accessible, MS/MS studies have mostly been done on the
following parasite preparations: schizonts, trophozoites, merozoites, infected erythrocytes, or sporozo-
ites. For ease of analysis, all proteins identiﬁed in schizont, trophozoite, merozoite, and infected
erythrocyte samples were simply denoted blood-stage proteins, while all proteins identiﬁed in sporozoite
parasite sample preparations were denoted sporozoites. To get an overall idea of the stage of expression
for the proteins recognized by CPS-immunized subjects, we compared the 4,216 proteins with MS/MS
evidence with unique proteins printed on the array and recognized by either at least 25% of the
responder groups or at least 25% of protected and nonprotected subjects.
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